JP2024038503A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2024038503A5 JP2024038503A5 JP2024011014A JP2024011014A JP2024038503A5 JP 2024038503 A5 JP2024038503 A5 JP 2024038503A5 JP 2024011014 A JP2024011014 A JP 2024011014A JP 2024011014 A JP2024011014 A JP 2024011014A JP 2024038503 A5 JP2024038503 A5 JP 2024038503A5
- Authority
- JP
- Japan
- Prior art keywords
- cells
- tumor antigen
- specific
- population
- percentage
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962845251P | 2019-05-08 | 2019-05-08 | |
| US62/845,251 | 2019-05-08 | ||
| PCT/US2020/031898 WO2020227546A1 (en) | 2019-05-08 | 2020-05-07 | T cell manufacturing compositions and methods |
| JP2021566008A JP7582971B2 (ja) | 2019-05-08 | 2020-05-07 | T細胞製造組成物および方法 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021566008A Division JP7582971B2 (ja) | 2019-05-08 | 2020-05-07 | T細胞製造組成物および方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024038503A JP2024038503A (ja) | 2024-03-19 |
| JP2024038503A5 true JP2024038503A5 (cg-RX-API-DMAC7.html) | 2024-05-28 |
| JP7855622B2 JP7855622B2 (ja) | 2026-05-08 |
Family
ID=73051205
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021566008A Active JP7582971B2 (ja) | 2019-05-08 | 2020-05-07 | T細胞製造組成物および方法 |
| JP2024011014A Active JP7855622B2 (ja) | 2019-05-08 | 2024-01-29 | T細胞製造組成物および方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021566008A Active JP7582971B2 (ja) | 2019-05-08 | 2020-05-07 | T細胞製造組成物および方法 |
Country Status (15)
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2772076A1 (en) | 2009-08-24 | 2011-03-10 | Baylor College Of Medicine | Generation of ctl lines with specificity against multiple tumor antigens or multiple viruses |
| GB201121308D0 (en) | 2011-12-12 | 2012-01-25 | Cell Medica Ltd | Process |
| EP2812431B1 (en) | 2012-02-09 | 2019-07-17 | Baylor College Of Medicine | Pepmixes to generate multiviral ctls with broad specificity |
| US11167024B2 (en) | 2015-09-18 | 2021-11-09 | Baylor College Of Medicine | Immunogenic antigen identification from a pathogen and correlation to clinical efficacy |
| WO2021178701A1 (en) * | 2020-03-05 | 2021-09-10 | Exuma Biotech Corp. | Methods and compositions for the delivery of modified lymphocyte aggregates |
| JP7054418B2 (ja) | 2017-11-08 | 2022-04-13 | ビオンテック ユーエス インコーポレイテッド | T細胞を製造する組成物及び方法 |
| KR20210040355A (ko) * | 2018-06-19 | 2021-04-13 | 바이오엔테크 유에스 인크. | 네오항원 및 이의 용도 |
| TWI867324B (zh) | 2019-05-08 | 2024-12-21 | 美商百歐恩泰美國公司 | T細胞製備組合物及方法 |
| WO2021222479A1 (en) | 2020-04-28 | 2021-11-04 | Lyell Immunopharma, Inc. | Methods for culturing cells |
| JP2023539056A (ja) * | 2020-08-13 | 2023-09-13 | ビオンテック ユーエス インコーポレイテッド | T細胞を製造する組成物および方法 |
| US11948694B2 (en) * | 2021-05-12 | 2024-04-02 | Merative Us L.P. | Controlling compartmental flows in epidemiological modeling based on mobility data |
| US12062456B2 (en) | 2021-05-27 | 2024-08-13 | Merative Us L.P. | Hypothetical scenario evaluation in infectious disease dynamics based on similar regions |
| IL312121A (en) * | 2021-10-15 | 2024-06-01 | Biontech Us Inc | T cell manufacturing compositions and methods |
| WO2023159088A1 (en) * | 2022-02-15 | 2023-08-24 | Marker Therapeutics, Inc. | Compositions and methods for antigen-specific t cell expansion |
| JP2026500232A (ja) * | 2022-12-09 | 2026-01-06 | ビオンテック ユーエス インコーポレイテッド | T細胞を製造する組成物および方法 |
| KR20240112760A (ko) * | 2023-01-12 | 2024-07-19 | 주식회사 이뮤노맥스 | 항암능이 우수한 기억 t 세포 유래 면역세포치료제의 제조방법 |
| CN117417886B (zh) * | 2023-10-20 | 2024-05-14 | 广东壹加再生医学研究院有限公司 | 一种负载肿瘤抗原的树突状细胞激活的t淋巴细胞的培养方法 |
| WO2025245488A2 (en) * | 2024-05-24 | 2025-11-27 | Biontech Us Inc. | Compositions and methods for t cell manufacturing and uses thereof |
Family Cites Families (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9022788D0 (en) | 1990-10-19 | 1990-12-05 | Cortecs Ltd | Pharmaceutical formulations |
| PT633929E (pt) | 1992-04-01 | 2004-07-30 | Merix Bioscience Inc | Metodo para proliferacao (in vitro) de precursores de celulas dentifricas e sua utilizacao para produzir imunogenios |
| IL106610A0 (en) | 1992-08-07 | 1993-12-08 | Cytel Corp | Hla binding peptides and their uses |
| SG49008A1 (en) | 1993-03-05 | 1998-05-18 | Cytel Corp | Hla-a2.1 binding peptides and their uses |
| US5849589A (en) | 1996-03-11 | 1998-12-15 | Duke University | Culturing monocytes with IL-4, TNF-α and GM-CSF TO induce differentiation to dendric cells |
| US6406705B1 (en) | 1997-03-10 | 2002-06-18 | University Of Iowa Research Foundation | Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant |
| US7745140B2 (en) | 2002-01-03 | 2010-06-29 | The Trustees Of The University Of Pennsylvania | Activation and expansion of T-cells using an engineered multivalent signaling platform as a research tool |
| EP1545610A4 (en) | 2002-09-06 | 2006-11-08 | Mannkind Corp | EPITOPE SEQUENCES |
| US7276478B2 (en) * | 2003-09-25 | 2007-10-02 | Zymogenetics, Inc. | Methods of treating autoimmune diseases using IL-21 |
| AU2005250408B2 (en) | 2004-05-27 | 2010-09-23 | The Trustees Of The University Of Pennsylvania | Novel artificial antigen presenting cells and uses therefor |
| WO2006015497A1 (en) | 2004-08-13 | 2006-02-16 | Val-Chum, S.E.C. | Methods of use of a dkk1 protein, immunogenic polypeptides thereof, nucleic acid encoding the dkk1 protein or polypeptides, or ligands thereof for detecting tumors; and for eliciting immune response against tumors |
| US20060286089A1 (en) * | 2005-04-08 | 2006-12-21 | Xcyte Therapies, Inc. | Compositions and methods for the treatment of burns and sepsis |
| DE102005046490A1 (de) * | 2005-09-28 | 2007-03-29 | Johannes-Gutenberg-Universität Mainz | Modifikationen von RNA, die zu einer erhöhten Transkriptstabilität und Translationseffizienz führen |
| CA2643337C (en) | 2006-03-01 | 2016-01-12 | Janssen Pharmaceutica N.V. | Cancer treatment combining lymphodepleting agent with ctls and cytokines |
| US9809797B2 (en) * | 2007-10-03 | 2017-11-07 | National Institutes Of Health (Nih) U.S. Dept. Of Health And Human Services (Dhhs) Division Of Extramural Inventions And Technology | Enhanced generation of cytotoxic T-lymphocytes by IL-21 mediated FOXP3 suppression |
| WO2009106073A2 (en) | 2008-02-28 | 2009-09-03 | Dako Denmark A/S | Mhc multimers in borrelia diagnostics and disease |
| EP2490713A2 (en) | 2009-10-23 | 2012-08-29 | MannKind Corporation | Cancer immunotherapy and method of treatment |
| US9115402B2 (en) | 2010-05-14 | 2015-08-25 | Dana-Farber Cancer Institute, Inc. | Compositions and methods of identifying tumor specific neoantigens |
| WO2012159643A1 (en) | 2011-05-24 | 2012-11-29 | Biontech Ag | Individualized vaccines for cancer |
| SG11201404570WA (en) * | 2012-02-10 | 2014-11-27 | Hakushinkouseikai Foundation | Proliferating agent for monocyte, culture medium for proliferating monocyte, method for producing monocyte, method for producing dendritic cell, and method for producing dendritic cell vaccine |
| WO2015039100A1 (en) | 2013-09-16 | 2015-03-19 | The Trustees Of The University Of Pennsylvania | Cd137 enrichment for efficient tumor infiltrating lymphocyte selection |
| US20150104441A1 (en) | 2013-10-11 | 2015-04-16 | Oslo Universitetssykehus Hf | Identification of disease-driving antigens |
| JP7060324B2 (ja) | 2013-12-20 | 2022-04-26 | ザ・ブロード・インスティテュート・インコーポレイテッド | ネオ抗原ワクチンによる併用療法 |
| US10627411B2 (en) | 2014-03-27 | 2020-04-21 | British Columbia Cancer Agency Branch | T-cell epitope identification |
| IL292038B2 (en) | 2014-04-23 | 2024-12-01 | Juno Therapeutics Inc | Methods for enriching or producing immune cell populations for adoptive therapy |
| JP6661544B2 (ja) | 2014-04-24 | 2020-03-11 | ミルテニイ バイオテック ゲゼルシャフト ミット ベシュレンクテル ハフツング | 遺伝子改変したt細胞の自動生成法 |
| CN103923880B (zh) | 2014-05-08 | 2016-03-30 | 成都百赛泰科生物科技有限公司 | 一种高效增殖、靶向杀伤肿瘤的ctl制备方法 |
| SG11201702191YA (en) | 2014-09-17 | 2017-04-27 | Univ Johns Hopkins | Reagents and methods for identifying, enriching, and/or expanding antigen-specific t cells |
| CN107075479A (zh) | 2014-10-02 | 2017-08-18 | 美国卫生和人力服务部 | 分离对癌症特异性突变具有抗原特异性的t细胞的方法 |
| WO2016168595A1 (en) | 2015-04-17 | 2016-10-20 | Barrett David Maxwell | Methods for improving the efficacy and expansion of chimeric antigen receptor-expressing cells |
| CA3172682A1 (en) | 2015-04-23 | 2016-10-27 | Nantomics, Llc | Cancer neoepitopes |
| CA3172801A1 (en) | 2015-06-12 | 2016-12-15 | Lentigen Technology, Inc. | Method to treat cancer with engineered t-cells |
| US10829735B2 (en) | 2015-07-21 | 2020-11-10 | The Trustees Of The University Of Pennsylvania | Methods for improving the efficacy and expansion of immune cells |
| DE102015214780A1 (de) * | 2015-08-03 | 2017-02-09 | Continental Automotive Gmbh | Verfahren zur Erkennung fehlerhafter Komponenten eines Kraftstoffeinspritzsystems |
| EP3335725B1 (en) | 2015-08-10 | 2024-02-28 | Toray Industries, Inc. | Pds5a epitopes as immunity inducers |
| KR20180043800A (ko) | 2015-09-09 | 2018-04-30 | 이뮨 디자인 코포레이션 | Ny-eso-1 특이적 tcrs 및 그의 사용 방법 |
| AU2016319126A1 (en) | 2015-09-10 | 2018-04-19 | Affigen, Inc. | Sequencing-directed selection of tumor theranostics |
| WO2017059557A1 (en) * | 2015-10-09 | 2017-04-13 | Peking University | Methods for enhancing in vivo persistence and efficacy of exogenously administered t cells, genetically modified t cells and method and method of use |
| SG11201808196UA (en) | 2016-03-31 | 2018-10-30 | Neon Therapeutics Inc | Neoantigens and methods of their use |
| WO2017177337A1 (en) | 2016-04-15 | 2017-10-19 | Zymeworks Inc. | Multi-specific antigen-binding constructs targeting immunotherapeutics |
| AU2017254477A1 (en) | 2016-04-18 | 2018-11-01 | Jennifer G. ABELIN | Improved HLA epitope prediction |
| JP7054397B2 (ja) | 2016-06-27 | 2022-04-13 | ジュノー セラピューティクス インコーポレイテッド | Mhc-e拘束性エピトープ、結合分子ならびに関連する方法および使用 |
| AU2017305396A1 (en) | 2016-08-02 | 2019-02-21 | Nant Holdings Ip, Llc | Transfection of dendritic cells and methods therefor |
| CN110809716B (zh) | 2017-02-12 | 2023-07-07 | 百欧恩泰美国公司 | 基于hla的方法和组合物及其用途 |
| US11236145B2 (en) | 2017-03-23 | 2022-02-01 | Immatics Biotechnologies Gmbh | T cell receptors and immune therapy using the same against PRAME positive cancers |
| BR112020005552A2 (pt) * | 2017-09-20 | 2020-10-27 | Neximmune, Inc. | composições de células compreendendo células t específicas de antígeno para terapia adotiva |
| JP7054418B2 (ja) | 2017-11-08 | 2022-04-13 | ビオンテック ユーエス インコーポレイテッド | T細胞を製造する組成物及び方法 |
| US20210171909A1 (en) | 2018-08-31 | 2021-06-10 | Novartis Ag | Methods of making chimeric antigen receptor?expressing cells |
| CA3124457A1 (en) | 2018-12-21 | 2020-06-25 | Biontech Us Inc. | Method and systems for prediction of hla class ii-specific epitopes and characterization of cd4+ t cells |
| US20220282217A1 (en) | 2019-03-30 | 2022-09-08 | Biontech Us Inc. | Compositions and methods for preparing t cell compositions and uses thereof |
| TWI867324B (zh) | 2019-05-08 | 2024-12-21 | 美商百歐恩泰美國公司 | T細胞製備組合物及方法 |
| US20230398218A1 (en) | 2020-08-13 | 2023-12-14 | Biontech Us Inc. | Ras neoantigens and uses thereof |
| JP2023539056A (ja) | 2020-08-13 | 2023-09-13 | ビオンテック ユーエス インコーポレイテッド | T細胞を製造する組成物および方法 |
| IL312121A (en) | 2021-10-15 | 2024-06-01 | Biontech Us Inc | T cell manufacturing compositions and methods |
| JP2026500232A (ja) | 2022-12-09 | 2026-01-06 | ビオンテック ユーエス インコーポレイテッド | T細胞を製造する組成物および方法 |
-
2020
- 2020-05-05 TW TW111130596A patent/TWI867324B/zh active
- 2020-05-05 TW TW109114957A patent/TWI777160B/zh active
- 2020-05-05 AR ARP200101269A patent/AR118859A1/es unknown
- 2020-05-07 MX MX2021013608A patent/MX2021013608A/es unknown
- 2020-05-07 CA CA3137037A patent/CA3137037A1/en active Pending
- 2020-05-07 KR KR1020247036158A patent/KR20240161214A/ko active Pending
- 2020-05-07 PH PH1/2021/552829A patent/PH12021552829A1/en unknown
- 2020-05-07 AU AU2020268397A patent/AU2020268397A1/en active Pending
- 2020-05-07 WO PCT/US2020/031898 patent/WO2020227546A1/en not_active Ceased
- 2020-05-07 SG SG11202112346WA patent/SG11202112346WA/en unknown
- 2020-05-07 US US17/609,705 patent/US12653887B2/en active Active
- 2020-05-07 BR BR112021022363A patent/BR112021022363A2/pt unknown
- 2020-05-07 JP JP2021566008A patent/JP7582971B2/ja active Active
- 2020-05-07 CN CN202511339181.5A patent/CN121086984A/zh active Pending
- 2020-05-07 CN CN202080050310.8A patent/CN114096261B/zh active Active
- 2020-05-07 EP EP20801696.4A patent/EP3965784A4/en active Pending
- 2020-05-07 KR KR1020217040167A patent/KR102756321B1/ko active Active
-
2021
- 2021-11-07 IL IL287874A patent/IL287874A/en unknown
-
2024
- 2024-01-29 JP JP2024011014A patent/JP7855622B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Saggau et al. | Autoantigen-specific CD4+ T cells acquire an exhausted phenotype and persist in human antigen-specific autoimmune diseases | |
| Maus et al. | HLA tetramer-based artificial antigen-presenting cells for stimulation of CD4+ T cells | |
| Sun et al. | MHC class II restricted neoantigen: a promising target in tumor immunotherapy | |
| JP2024041873A5 (cg-RX-API-DMAC7.html) | ||
| JP2021502414A5 (cg-RX-API-DMAC7.html) | ||
| JP2025061689A (ja) | 変異型rasを標的とするための組成物および方法 | |
| Reutner et al. | CD27 expression discriminates porcine T helper cells with functionally distinct properties | |
| JP5634415B2 (ja) | 腫瘍の治療のための細胞治療方法 | |
| EP2899269B1 (en) | Method for cloning t cell receptor | |
| JP2021520849A5 (cg-RX-API-DMAC7.html) | ||
| CN109715788A (zh) | 用于免疫疗法的t细胞组合物 | |
| Toso et al. | MAGE-1-specific precursor cytotoxic T-lymphocytes present among tumor-infiltrating lymphocytes from a patient with breast cancer: characterization and antigen-specific activation | |
| JP2022531474A5 (cg-RX-API-DMAC7.html) | ||
| JP2024538129A5 (cg-RX-API-DMAC7.html) | ||
| JP2023539056A5 (cg-RX-API-DMAC7.html) | ||
| Ajith et al. | Humanized mouse model as a novel approach in the assessment of human allogeneic responses in organ transplantation | |
| JP2023017853A (ja) | 新規な癌抗原及び方法 | |
| Bacsi et al. | Complexes of heparin and platelet factor 4 specifically stimulate T cells from patients with heparin-induced thrombocytopenia/thrombosis | |
| JP2022540396A (ja) | 新規な癌抗原及び方法 | |
| JP2022527364A (ja) | T細胞受容体遺伝子アセンブリのための組成物及び方法 | |
| Boehm et al. | Concurrent vaccination with two distinct vaccine platforms targeting the same antigen generates phenotypically and functionally distinct T-cell populations | |
| Zhang et al. | A polyclonal anti‐vaccine CD4 T cell response detected with HLA‐DP4 multimers in a melanoma patient vaccinated with MAGE‐3. DP4‐peptide‐pulsed dendritic cells | |
| Fontaine et al. | Regulatory T cells constrain the TCR repertoire of antigen‐stimulated conventional CD4 T cells | |
| JP6878544B2 (ja) | がん特異的突然変異に対し抗原特異性を有するt細胞を単離する方法 | |
| CN115667288A (zh) | 抗原池 |